Mycophenolate mofetil as a treatment for autoimmune haemolytic anaemia in patients with systemic lupus erythematosus and antiphospholipid syndrome

Abstract

Unresponsive autoimmune haemolytic anaemia (AIHA) may require therapy with second-line drugs. There is no consensusthat any one of these agents is more effectivethan another. Mycophenolatemofetil (MMF) is an immunosuppressivedrug proven to be effectivein reducing renal allograftrejectionas well as being used in autoimmune diseases including systemic lupus erythematosus (SLE). We describe its use in two patients who were treated with MMF for AIHA in the context of underlying SLE and antiphospholipid syndrome (APS). The patients showed a good response to treatment with MMF, suggesting a possible role in the treatment of AIHA.

Keywords

autoimmune haemolytic anaemia lupus mycophenolate mofetil

Get full access to this article

View all access options for this article.

References

Keeling DM , Isenberg DA. Haematological manifestations of systemic lupus erythematosus . Blood Rev 1993; 7: 199-207 .

Drenkard C , Villa AR , Alarcon Segovia D et al. influence of the antiphospholipid syndrome in the survival of patients with systemic lupus erythematosus . J Rheumatol 1994; 21: 1067-1072 .

Roldan R , Roman J , Lopez D et al. Treatment of hemolytic anemia and severe thrombocytopenia with high dose methylprednisolone and intravenous immunoglobulins in SLE . Scand J Rheumatol 1994; 23: 218-219 .

Halloran P , Mathew T , Tomlanovich S et al. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomised double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups . Transplantation 1997; 63: 39-47 .

Smak Gregoor PJH , van Gelder T , Weimar W. Mycophenolate mofetil, Cellcept, a new immunosuppressive drug with great potential in internal medicine . Netherlands J Med 2000; 57: 233-246 .

Karim MY , Alba P , Cuadrado MJ et al. Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents . Rheumatology (Oxford) 2002; 41: 876-882 .

Allison AC , Eugui EM. Purine metabolism and immunosuppressive effects of mycophenolate mofetil . Transplant 1996; 10: 77-84 .

Chan TM , Li FK , Tang CS et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group . N Engl J Med 2000; 34: 1156-1162 .

Zimmer-Molsberger B , Knauf W , Thiel E. Mycophenolate mofetil for severe autoimmune haemolytic anaemia . Lancet 1997; 350: 1003-1004 .

10.

Howard J , Hoffbran AV , Prentice HG et al. Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anaemia and auto-immune thrombocytopenia purpura . Br J Haematol 2002; 117: 712-715 .

11.

Arbeiter K , Greenbaum L , Balzar E et al. Reproducible erythroid aplasia caused by mycophenolate mofetil . Pediatr Nephrol 2000; 14: 195-197 .

12.

Kokori SIG , Ioannidis JPA , Voulgarelis M et al. Autoimmune hemolytic anemia in patients with systemic lupus erythematosus . Am J Med 2000; 108: 198-203 .